Thanks for the interesting discussion on shorts and longs. I won't claim to understand how to translate that into whether to buy or sell. For what it's worth, most biotech was down today and XL was right in the middle. Big pharma was up though Amgen and Biogen Idec were down. Go figure. Could have to do with elections, Fed announcements, or who knows.

I'll also say that I believe the driver of price around ASCO was actually the PI3KI deal and the early XL184 GBM data. THe latter quickly turned into bad news as expectations were raised too high. My hope is that the hints of good lung data with XL184 aren't overblown, but we'll need to wait and see.

The "wiz"